New method enables easier and faster detection of celiac disease antibodies

November 26, 2019

Point-of-care (POC) testing is a rapidly growing sector, bringing medical testing from central laboratories to where the patient is receiving care.

Researchers from the University of Helsinki have developed a novel diagnostic method coined RFS (Rapid FRET serodiagnostics) for the rapid on-site measurement of antibodies from patient samples. This technology could revolutionize the serodiagnosis of microbial, autoimmune and allergic disorders.

Now this team of researchers have applied the new concept for diagnostics of celiac disease.

MOST PATIENTS ARE UNAWARE OF THEIR CELIAC DISEASE

Celiac disease is an autoimmune disorder typically presenting as non-specific gastrointestinal symptoms. It affects approximately 1 % of world population, with more than 90 % of patients undiagnosed. Even in affluent countries, more than half of celiacs are unaware of their disease. Delayed diagnosis is associated with impaired quality of life and persistent symptoms even after treatment.

Screening of celiac disease is recommended for patients with e.g. gastrointestinal symptoms or other autoimmune diseases as well as for the first-degree relatives of celiac patients. The screening test involves measurement of disease-specific antibodies from a blood sample.

EASY AND FASTER DETECTION OF CELIAC DISEASE ANTIBODIES

The researchers gathered samples from 70 celiacs at the Kuopio University Hospital, half from children and half from adults. Control samples from healthy donors were also collected. The samples were measured using the new assay and results compared with two currently used methods.

"The performance of the test was comparable to that of current methods. The prevailing method involves transporting the sample to a central laboratory and a multi-step procedure taking hours. With the new method, results can be achieved in less than half an hour by simply combining the sample and a reagent mix, waiting for a while and reading the result.", Juuso Rusanen, MD, explains. He continues:

"We hope our rapid method could lower the threshold for screening of celiac disease and thus help overcome the vast underdiagnosis of this relatively common condition."

"Additionally, this is the first time the new method has been used for diagnostics of autoimmune disease. This is a promising result, and prompts the development of similar tests for diagnostics of other autoimmune disorders", Rusanen points out.
-end-


University of Helsinki

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.